CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
and domvanalimab in combination with zimberelimab and etrumadenant (AB928) in front-line, PD-L1 positive, metastatic non-small cell lung cancer...
Phase 2
Taipei, Taiwan and 64 other locations
This is a study of the efficacy, pharmacokinetics, and safety of DS-1062a in participants with advanced or metastatic non-small cell lung ca...
Phase 2
Taipei City, Taiwan and 83 other locations
The main purpose of this study is to evaluate the safety, tolerability, and recommended phase 2 target dose of tarlatamab in combination with AMG 404.
Phase 1
Taipei, Taiwan and 16 other locations
This study was designed to evaluate the safety and efficacy of trastuzumab deruxtecan in HER2-mutated metastatic non-small cell lung cancer...
Phase 2
Taipei City, Taiwan and 47 other locations
with previously treated advanced or metastatic non-small cell lung cancer (NSCLC) with or without actionable genomic alterations....
Phase 3
Taipei, Taiwan and 205 other locations
The primary objective of this study is to compare the efficacy of tarlatamab with placebo as assessed by progression free survival (PFS).
Phase 3
Taipei, Taiwan and 29 other locations
with pemetrexed and platinum chemotherapy in participants with no prior therapy for advanced or metastatic non-squamous non-small cell lung ...
Phase 3
Taipei, Taiwan and 139 other locations
This is a phase 3 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) compared to pembrolizumab in front-line, PD-L1-high, loca...
Phase 3
Taipei, Taiwan and 170 other locations
to docetaxel in participants with advanced non-small cell lung cancer (NSCLC) harboring a KRAS G12C mutation who have been previous...
Phase 3
Taipei, Taiwan and 155 other locations
This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...
Phase 2
Taipei, Taiwan and 122 other locations
Clinical trials
Research sites
Resources
Legal